Vitae Pharmaceuticals Inc. (VTAE) is on track to report top-line clinical efficacy and preliminary biomarker results from its multiple ascending dose, clinical proof-of-concept trial of VTP-43742 in psoriatic patients by the end of the first quarter of 2016.
from RTT - Biotech http://ift.tt/21IcM8B
via IFTTT
No comments:
Post a Comment